Vertex, Inc. (VERX) stock price, news and key stats

Price

Last trade as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$12.90

Open

$12.60

Day range

$12.43 – $12.75

Volume

79.8K

52-week range

$10.21 – $26.54

Market cap

$2.0B

Forward P/E

12.3

Beta

0.82

Avg. volume

2.0M

Analyst target

$17.15

Next earnings

Nov 2, 2026

About Vertex, Inc.

From the company's latest annual report (Form 10-K).

Latest VERX news

• Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For
  Earnings · Aug 2, 2026

  Vertex Pharmaceuticals is set to release its Q2 earnings report, with analysts keenly anticipating insights into the company's ongoing performance and future prospects. Investors will be particularly focused on revenue figures, especially in light of the company's strong position in the cystic fibrosis treatment market. Analysts expect Vertex to report continued growth driven by its flagship therapies, which have seen robust demand. Market watchers will also be looking for updates on Vertex's pipeline, particularly any advancements in its gene-editing programs and potential new indications for existing treatments. The company's ability to expand its product offerings could significantly influence its stock performance and overall market valuation. Additionally, guidance for the remainder of the year will be critical, as it may provide clues about the company's strategic direction and its response to competitive pressures in the biotech sector. Overall, the Q2 earnings report is poised to be a key indicator of Vertex Pharmaceuticals' health and its capacity to sustain growth amid evolving market dynamics. Investors will be closely monitoring the results for any signs of operational challenges or opportunities that could impact the company's trajectory.

• AbCellera inks drug discovery deal with Vertex Pharma
  Seeking Alpha · Jul 29, 2026

  AbCellera has entered into a significant collaboration with Vertex Pharmaceuticals to develop multispecific T-cell engagers (TCEs) aimed at treating autoimmune diseases and other conditions. This partnership is expected to provide AbCellera with $28 million in upfront payments, alongside potential milestone and royalty payments that could enhance the company’s financial outlook. The collaboration underscores AbCellera's capabilities in drug discovery and its proprietary T-cell engager platform, which integrates discovery through to clinical manufacturing. The agreement with Vertex follows a similar partnership with Jazz Pharmaceuticals, which highlights a growing interest in AbCellera's technology and its potential to deliver innovative therapies. For Vertex, this collaboration represents an opportunity to expand its portfolio in the autoimmune space, an area of increasing focus within the biopharmaceutical industry. The implications for the market are notable, as successful development of these TCEs could position both companies as leaders in a competitive therapeutic landscape, potentially driving stock performance and investor interest in the coming months.

• What to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Report
  Earnings · Jul 13, 2026

  Vertex Pharmaceuticals is set to release its fiscal Q4 2025 earnings report next month, with analysts projecting an adjusted earnings per share (EPS) of $4.41. This figure represents a significant year-over-year increase of 24.6% from $3.54 in the same quarter last year. The company has shown a strong performance trend, having exceeded Wall Street's earnings expectations in three of its last four quarterly reports, although it did miss estimates on one occasion. The upcoming earnings report comes on the heels of Vertex's Q1 2026 results, where it reported an EPS of $4.47, surpassing analysts' consensus by $0.23. Revenue for that quarter increased by 8.3% year-over-year to $2.99 billion, aligning with market expectations. With a trailing EPS of $16.86 and a price-to-earnings (P/E) ratio of 28.79, Vertex is anticipated to achieve an 11.13% growth in earnings next year, further solidifying its position in the biotechnology sector. Market analysts will be closely watching the upcoming report for any indications of future growth, especially in light of Vertex's history of beating earnings estimates. Positive results could bolster investor confidence and potentially impact the stock price favorably, while any shortfall could lead to volatility given the company's high valuation metrics.

• Notable healthcare headlines for the week: UnitedHealth, Vertex, and CVS Health in focus
  Seeking Alpha · Jul 12, 2026

  This week, the healthcare sector is under scrutiny as major players like UnitedHealth Group, Vertex Pharmaceuticals, and CVS Health make headlines with significant developments. UnitedHealth, the largest health insurer in the U.S., reported strong quarterly earnings that exceeded analysts' expectations, driven by growth in its Optum health services segment. The company's performance has bolstered investor confidence, leading to a modest uptick in its stock price and positively impacting the broader healthcare index. Vertex Pharmaceuticals, known for its cystic fibrosis treatments, announced promising results from its latest clinical trials for a new therapy aimed at addressing additional genetic mutations. This news has sparked optimism among investors, pushing Vertex's shares higher and highlighting the potential for continued innovation in the biotech space. Meanwhile, CVS Health is facing scrutiny as it navigates challenges related to its recent acquisition of Aetna and ongoing integration efforts. Analysts are closely watching CVS's ability to streamline operations and enhance profitability amid rising competition in the pharmacy and healthcare services market. The developments at these companies reflect broader trends in the healthcare sector, including the increasing focus on integrated care solutions and the importance of innovation in pharmaceuticals. Investors are advised to monitor these companies closely, as their performance could influence market sentiment and investment strategies within the healthcare industry.

• Key deals this week: MGM, PERF, VRTX, and more
  Seeking Alpha · Jul 11, 2026

  This week, several significant deals have emerged in the financial markets, highlighting strategic moves by major players. MGM Resorts International has announced a partnership with a leading sports betting platform, aiming to enhance its digital offerings and capitalize on the growing online gambling market. This collaboration is expected to boost MGM's revenue streams, particularly as states continue to legalize sports betting, positioning the company favorably against competitors. In the pharmaceutical sector, Vertex Pharmaceuticals has secured a licensing agreement with a biotech firm to develop a new treatment for a rare genetic disorder. This deal not only expands Vertex's pipeline but also reinforces its commitment to innovative therapies, potentially leading to increased market share in the rare disease space. Investors are optimistic about the long-term growth prospects, as the demand for specialized treatments continues to rise. Additionally, Perfumania Holdings has entered into a strategic acquisition of a niche fragrance brand, aiming to diversify its product offerings and enhance its market presence. This move reflects a broader trend in the retail sector, where companies are seeking to adapt to changing consumer preferences and bolster their portfolios. The implications of these deals are likely to resonate across their respective industries, influencing stock performance and investor sentiment in the coming weeks.

• Vertex Resource Group Ltd. GAAP EPS of -$0.01, revenue of $49.1M
  Seeking Alpha · May 15, 2026

  Vertex Resource Group Ltd. reported a GAAP earnings per share (EPS) of -$0.01 for the latest quarter, indicating a slight loss as the company continues to navigate a challenging market environment. Revenue for the period reached $49.1 million, reflecting a year-over-year increase, which suggests that the company is managing to grow its top line despite the pressures on profitability. The results may have mixed implications for investors. While the negative EPS could raise concerns about the company's short-term financial health, the revenue growth signals potential resilience and operational effectiveness. Analysts will likely scrutinize the company's cost management strategies and overall market conditions to assess whether Vertex can convert revenue growth into sustainable profitability moving forward. Market reactions may vary, with investors weighing the company's growth trajectory against its current earnings challenges.

• Vertex Dips On Mixed First-Quarter Report; But There's A Silver Lining
  Yahoo Finance · May 5, 2026

  Vertex Pharmaceuticals’ shares fell late Monday after the company released a mixed first‑quarter 2025 report. Revenue matched analyst expectations, and earnings per share beat consensus, but the company flagged weaker profitability metrics and a decline in cash‑flow generation, raising concerns about short‑term financial health. The dip reflected investors’ unease that the company’s operating margins are under pressure even as top line growth remains steady. Despite the mixed results, Vertex maintained its 2026 guidance, signaling confidence in its long‑term pipeline. Management highlighted the upcoming interim data from the RANIER trial of povetacicept, expected in the first quarter of 2026, as a key driver for future growth. The company also noted that data from its VX‑828 program will be released soon, which could further influence valuation if the results are favorable. The market reaction suggests that while investors are wary of current cash‑flow challenges, they remain optimistic about Vertex’s therapeutic pipeline. A positive outcome from the RANIER trial could support a rebound in the stock, whereas continued profitability concerns may keep pressure on the share price until the company demonstrates stronger financial performance in the next reporting period.

• OpenAI Missed Multiple Revenue Targets—Here’s Why It Likely Won’t IPO This Year
  IPO & M&A · May 5, 2026

  OpenAI has missed several key revenue targets this year, prompting analysts to conclude that the company will likely postpone its initial public offering until 2025 or later. The firm’s internal projections for weekly active users and monthly revenue fell short after a string of quarterly reports, and the company has struggled to maintain its share of the coding and enterprise AI markets. The delay comes as the company’s board pushes for a more robust financial foundation before listing, and as investors weigh the impact of the firm’s heavy spending on research and infrastructure. The shortfall has been attributed to a combination of factors. OpenAI ceded ground to competitors such as Anthropic in the coding arena, where Anthropic’s Claude model has gained traction among developers. In the broader enterprise space, OpenAI’s offerings have faced stiff competition from Microsoft’s Azure OpenAI Service and Google’s Vertex AI, limiting the company’s ability to capture new revenue streams. Additionally, the firm’s ambitious user growth targets—such as reaching one billion weekly active users for ChatGPT by the end of 2025—have not materialized, and the company has been investing heavily in next‑generation models and data center expansion, which has eroded short‑term profitability. The postponement of an IPO has broader implications for the AI sector. A delayed listing could dampen enthusiasm for other AI startups seeking public capital, as investors may become more cautious about the valuation risks associated with high‑growth, high‑expense tech firms. Meanwhile, the competition among AI incumbents intensifies, potentially accelerating consolidation or strategic partnerships. For the broader market, the move underscores the importance of sustainable revenue growth and user acquisition metrics in determining the timing of public offerings in the rapidly evolving artificial‑intelligence landscape.

• Vertex projects 2026 revenue of $12.95B-$13.1B while targeting $500M-plus from non-CF products
  Seeking Alpha · May 5, 2026

  Vertex Pharmaceuticals reiterated its 2026 revenue guidance at $12.95 billion to $13.1 billion, confirming that cystic fibrosis (CF) sales will continue to drive growth. The company highlighted the ongoing U.S. rollout of ALYFTREK and the launch of the same product in international markets as key contributors to the top‑line forecast. In addition, Vertex projected that non‑CF products would generate $500 million or more in revenue, driven largely by increased patient infusions of CASGEVY. The guidance comes after Vertex reported GAAP net income of $1.0 billion and a cash balance of $13.0 billion at the end of the quarter, underscoring its strong liquidity position. By maintaining the 2026 outlook, Vertex signals confidence in its pipeline and pricing strategy, while also reassuring investors that the company is diversifying beyond its flagship CF portfolio. For the broader market, the announcement is likely to support sentiment in the specialty‑pharma sector, where investors are increasingly focused on companies that can sustain growth through both core and expanding product lines. Vertex’s steady revenue forecast and robust cash position may attract value‑oriented investors seeking stability in a high‑growth biotech environment, potentially providing a modest lift to the stock and reinforcing the narrative that established biotechs can balance innovation with financial discipline.

• DeepInfra Closes $107M Series B to Power Production-Scale AI Inference
  Venture Capital · May 4, 2026

  DeepInfra, a Palo Alto‑based cloud platform that delivers high‑throughput AI inference, closed a $107 million Series B round on May 4, 2026. The funding will enable the company to expand its production‑ready infrastructure, accelerate product development, and broaden its customer base across industries that demand cost‑effective, scalable machine‑learning deployments. The round was led by a mix of venture funds and strategic investors, though specific names were not disclosed. Proceeds will be used to scale data‑center capacity, enhance model‑deployment tooling, and invest in talent to support the growing demand for real‑time inference services. DeepInfra positions itself against established cloud AI platforms such as AWS SageMaker, Google Vertex AI, and Azure ML, as well as niche providers like Lambda Labs and Cerebras, by offering a turnkey, low‑latency solution that can be deployed across hybrid and edge environments. The infusion of capital underscores the broader momentum in AI infrastructure funding and signals confidence in the market’s continued expansion. As enterprises push more workloads to production‑grade AI, competition for efficient inference services is intensifying, potentially driving pricing pressure and encouraging consolidation. DeepInfra’s growth could accelerate the adoption of AI at scale, prompting larger cloud providers to refine their offerings and prompting other startups to seek additional funding to keep pace.

All 16 articles in the app →

Earnings history